Prévisions
L'objectif de cours moyen des analystes est de 64,98 € (+48,09 %). La médiane est de 64,71 € (+47,47 %).
| Acheter |
13 |
| Conserver |
2 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Scholar Rock clarifies FDA requirements for ISEMBYLD, shares fall sharply
Scholar Rock confirmed that the FDA requires post‑marketing conditions for ISEMBYLD, including a study on safety in pregnancy and 15‑day adverse‑event reporting for bone fractures. Management had previously (and incorrectly) stated that no such conditions existed. The stock then fell 6.4% to $51.85 and declined 9.7% on the week. Scholar Rock said it will carry out the requested studies and reporting in line with FDA requirements; analysts subsequently adjusted ratings and price targets. » Plus sur de.investing.com
FDA grants approval for ISEMBYLD; Scholar Rock stock rises
The FDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-specific treatment for spinal muscular atrophy in adults and children aged two and older who are already receiving an SMN2-directed therapy. The news pushed Scholar Rock’s stock up about 9% pre-market to $60.45 and converts the company into a commercial biopharma company. Several analysts sharply raised price targets and reiterated buy ratings; apitegromab is projected to generate billions in sales by 2035. Scholar Rock reports roughly $492 million in cash and has independent fill-and-finish and manufacturing capabilities for the product launch. » Plus sur de.investing.com
Scholar Rock receives FDA approval for Isembyld to treat SMA
The FDA has approved Isembyld (Apitegromab‑mstn) for the treatment of spinal muscular atrophy in patients aged two and older. The approval is based on the phase‑3 SAPPHIRE study, in which patients receiving Isembyld in addition to standard therapy showed a significant improvement on the Hammersmith scale after one year; 34.2% achieved an increase of at least three points versus 13.5% with placebo. The US commercial launch has begun, the stock climbed more than 14% to an all‑time high, and Scholar Rock is shifting from a clinical biotech company to a commercial drugmaker. » Plus sur deraktionaer.de
Scholar Rock prepares for FDA decision on apitegromab
Weeks before the PDUFA date on September 30, 2026, Scholar Rock highlights late Phase III data on apitegromab as well as secured commercial production and go‑to‑market infrastructure. After an earlier Complete Response Letter over manufacturing issues, the company moved commercial fill‑finish production to an alternative site and says it has already produced commercial vials there. Management emphasizes statistically significant Phase III results, high treatment adherence, and prepared sales, nursing and patient‑support structures for the US, with plans for Europe and Japan. » Plus sur de.investing.com
Scholar Rock nears approval for apitegromab
At the Cantor Fitzgerald Global Healthcare Conference, Scholar Rock said the FDA has identified compliance with manufacturing requirements as the only remaining approval hurdle and that the company has since established a contractually committed alternative fill-and-finish facility. The crucial PDUFA date is September 30, 2026; management is holding intensive talks with the FDA about labeling and safety data. Scholar Rock has roughly $500 million in cash, sees worldwide market potential in the billions, and expects initial but manageable reimbursement and market-access hurdles during the first three to five quarters after launch. » Plus sur de.investing.com
Données financières
Au dernier trimestre, SCHOLAR ROCK HLDG DL-,001 a réalisé un chiffre d'affaires de 503,22 k € et un bénéfice net de -94,68 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 503,22 k | - |
| Bénéfice brut | 496,16 k | 101,15 % |
| Bénéfice net | -94,68 M | 8,69 % |
| EBITDA | -90,36 M | 5,55 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 5,35 Md € |
Nombre d'actions | 122 M |
Plus haut/bas sur 52 semaines | 56,28 € - 35,26 € |
| Dividendes | Non |
Bêta | 0,62 |
Ratio P/E | -14,95 |
Ratio PEG | 28,66 |
Ratio P/B | 37,77 |
Ratio P/S | 10 301,85 |
Profil de l'entreprise
Scholar Rock Holding Corporation, une société biopharmaceutique, se concentre sur la découverte et le développement de médicaments destinés au traitement de maladies graves dans lesquelles la signalisation par les facteurs de croissance protéiques joue un rôle fondamental. La société développe l'Apitegromab, un inhibiteur de l'activation de la myostatine latente, qui a achevé les essais cliniques de phase 3 pour le traitement de l'amyotrophie spinale ; ainsi que le SRK-181, actuellement en essais cliniques de phase 1 pour le traitement de cancers résistants aux thérapies par inhibiteurs de points de contrôle immunitaires, telles que les thérapies par anticorps anti-PD-1 ou anti-PD-L1. Elle développe également un portefeuille de nouveaux candidats-médicaments susceptibles de transformer la vie de patients atteints d'une série de maladies graves, notamment les troubles neuromusculaires, le cancer et la fibrose. La société a conclu un accord de collaboration avec Gilead Sciences, Inc. afin de découvrir et de développer des inhibiteurs spécifiques de l'activation du facteur de croissance transformant bêta, destinés au traitement des maladies fibrotiques. Scholar Rock Holding Corporation a été fondée en 2012 et son siège social se situe à Cambridge, Massachusetts.
| Nom | SCHOLAR ROCK HLDG DL-,001 |
| PDG | David L. Hallal |
| Siège social | Cambridge,
ma États-Unis |
| Site web | |
| Secteur | Consommation de base |
| Industrie | Produits alimentaires |
| Introduction en bourse | 25/05/2018 |
| Employés | 289 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | SRRK |
Frankfurt | 2QK.F |
Düsseldorf | 2QK.DU |
München | 2QK.MU |